Sivik Global Healthcare LLC Trims Stock Position in Novo Nordisk A/S (NYSE:NVO)

Sivik Global Healthcare LLC lowered its position in Novo Nordisk A/S (NYSE:NVO) by 22.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 70,000 shares of the company’s stock after selling 20,000 shares during the period. Novo Nordisk A/S accounts for approximately 3.2% of Sivik Global Healthcare LLC’s portfolio, making the stock its 9th largest position. Sivik Global Healthcare LLC’s holdings in Novo Nordisk A/S were worth $6,021,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Capital Investment Advisory Services LLC boosted its position in shares of Novo Nordisk A/S by 4.4% during the 4th quarter. Capital Investment Advisory Services LLC now owns 9,919 shares of the company’s stock worth $853,000 after purchasing an additional 422 shares in the last quarter. Busey Bank raised its stake in Novo Nordisk A/S by 108.5% during the 4th quarter. Busey Bank now owns 106,434 shares of the company’s stock worth $9,155,000 after buying an additional 55,380 shares during the period. First Affirmative Financial Network boosted its holdings in Novo Nordisk A/S by 5.3% in the fourth quarter. First Affirmative Financial Network now owns 4,644 shares of the company’s stock worth $399,000 after acquiring an additional 233 shares in the last quarter. Abel Hall LLC boosted its holdings in Novo Nordisk A/S by 3.5% in the fourth quarter. Abel Hall LLC now owns 6,013 shares of the company’s stock worth $517,000 after acquiring an additional 206 shares in the last quarter. Finally, Highland Capital Management LLC raised its position in shares of Novo Nordisk A/S by 32.0% during the fourth quarter. Highland Capital Management LLC now owns 16,500 shares of the company’s stock worth $1,419,000 after purchasing an additional 4,000 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 0.6 %

Shares of Novo Nordisk A/S stock opened at $84.54 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The firm has a market cap of $379.38 billion, a PE ratio of 27.38, a PEG ratio of 0.90 and a beta of 0.45. The company has a 50 day simple moving average of $94.75 and a two-hundred day simple moving average of $114.02.

Analysts Set New Price Targets

Several brokerages recently weighed in on NVO. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.